BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J; for the Barcelona Cly'nic Liver Cancer (BCLC) Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-60. [DOI: 10.1002/hep.20465] [Cited by in Crossref: 330] [Cited by in F6Publishing: 279] [Article Influence: 19.4] [Reference Citation Analysis]
Number Citing Articles
1 Lu MD, Xu HX, Xie XY, Yin XY, Chen JW, Kuang M, Xu ZF, Liu GJ, Zheng YL. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol. 2005;40:1054-1060. [PMID: 16322950 DOI: 10.1007/s00535-005-1671-3] [Cited by in Crossref: 160] [Cited by in F6Publishing: 141] [Article Influence: 10.7] [Reference Citation Analysis]
2 Guglielmi A, Ruzzenente A, Sandri M, Pachera S, Pedrazzani C, Tasselli S, Iacono C. Radio frequency ablation for hepatocellular carcinoma in cirrhotic patients: prognostic factors for survival. J Gastrointest Surg. 2007;11:143-149. [PMID: 17390163 DOI: 10.1007/s11605-006-0082-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
3 Rodríguez-perálvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A Systematic Review of Microvascular Invasion in Hepatocellular Carcinoma: Diagnostic and Prognostic Variability. Ann Surg Oncol 2013;20:325-39. [DOI: 10.1245/s10434-012-2513-1] [Cited by in Crossref: 257] [Cited by in F6Publishing: 245] [Article Influence: 28.6] [Reference Citation Analysis]
4 Roayaie S, Llovet JM. Liver Transplantation for Hepatocellular Carcinoma: Is Expansion of Criteria Justified? Clinics in Liver Disease 2005;9:315-28. [DOI: 10.1016/j.cld.2004.12.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
5 Sapisochin G, de Sevilla EF, Echeverri J, Charco R. Management of “very early” hepatocellular carcinoma on cirrhotic patients. World J Hepatol. 2014;6:766-775. [PMID: 25429314 DOI: 10.4254/wjh.v6.i11.766] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
6 Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann R, Löhe F, Graeb C, Rau H, Schauer R, Jauch K, Caselmann WH, Göke B, Jüngst D. Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma. Digestion 2007;75:104-12. [DOI: 10.1159/000104730] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
7 Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. [PMID: 16799626 DOI: 10.1038/sj.onc.1209548] [Cited by in Crossref: 109] [Cited by in F6Publishing: 95] [Article Influence: 7.3] [Reference Citation Analysis]
8 Schaible J, Pregler B, Verloh N, Einspieler I, Bäumler W, Zeman F, Schreyer A, Stroszczynski C, Beyer L. Improvement of the primary efficacy of microwave ablation of malignant liver tumors by using a robotic navigation system. Radiol Oncol 2020;54:295-300. [PMID: 32463387 DOI: 10.2478/raon-2020-0033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Bartolotta TV, Taibbi A, Midiri M, De Maria M. Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound. Abdom Imaging. 2008;33:501-511. [PMID: 17786507 DOI: 10.1007/s00261-007-9294-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
10 Cha DI, Kang TW, Song KD, Lee MW, Rhim H, Lim HK, Sinn DH, Kim K. Radiofrequency ablation for subcardiac hepatocellular carcinoma: therapeutic outcomes and risk factors for technical failure. Eur Radiol 2019;29:2706-15. [PMID: 30506222 DOI: 10.1007/s00330-018-5868-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H, Yoshikawa M, Kondo F, Saisho H. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol. 2005;43:458-464. [PMID: 16005538 DOI: 10.1016/j.jhep.2005.03.033] [Cited by in Crossref: 129] [Cited by in F6Publishing: 106] [Article Influence: 8.1] [Reference Citation Analysis]
12 Park MJ, Kim YS, Lee WJ, Lim HK, Rhim H, Lee J. Outcomes of follow-up CT for small (5-10-mm) arterially enhancing nodules in the liver and risk factors for developing hepatocellular carcinoma in a surveillance population. Eur Radiol. 2010;20:2397-2404. [PMID: 20559837 DOI: 10.1007/s00330-010-1810-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
13 Himoto T, Kurokohchi K, Watanabe S, Masaki T. Recent advances in radiofrequency ablation for the management of hepatocellular carcinoma. Hepat Mon. 2012;12:e5945. [PMID: 23162600 DOI: 10.5812/hepatmon.5945] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
14 de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 191] [Article Influence: 40.3] [Reference Citation Analysis]
15 Nicolau C, Vilana R, Bianchi L, Brú C. Early-stage hepatocellular carcinoma: the high accuracy of real-time contrast-enhanced ultrasonography in the assessment of response to percutaneous treatment. Eur Radiol Suppl 2007;17:80-8. [DOI: 10.1007/s10406-007-0232-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
16 Meloni MF, Francica G, Chiang J, Coltorti A, Danzi R, Laeseke PF. Use of Contrast-Enhanced Ultrasound in Ablation Therapy of HCC: Planning, Guiding, and Assessing Treatment Response. J Ultrasound Med 2021;40:879-94. [PMID: 32936485 DOI: 10.1002/jum.15471] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
17 Lencioni R, Crocetti L, Petruzzi P, Vignali C, Bozzi E, Della Pina C, Bargellini I, Cioni D, Oliveri F, De Simone P, Bartolozzi C, Brunetto M, Filipponi F. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: A pilot clinical study. Journal of Hepatology 2008;49:217-22. [DOI: 10.1016/j.jhep.2008.03.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 53] [Article Influence: 5.7] [Reference Citation Analysis]
18 Sherman M. Optimizing Management Strategies in Special Patient Populations. Am J Gastroenterology 2006;101:S26-31. [DOI: 10.1111/j.1572-0241.2006.00369.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
19 Le Moigne F, Durieux M, Bancel B, Boublay N, Boussel L, Ducerf C, Berthezène Y, Rode A. Impact of diffusion-weighted MR imaging on the characterization of small hepatocellular carcinoma in the cirrhotic liver. Magnetic Resonance Imaging 2012;30:656-65. [DOI: 10.1016/j.mri.2012.01.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
20 Itoh S, Morita K, Ueda S, Sugimachi K, Yamashita Y, Gion T, Fukuzawa K, Wakasugi K, Taketomi A, Maehara Y. Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Ann Surg Oncol. 2009;16:3299-3307. [PMID: 19826875 DOI: 10.1245/s10434-009-0721-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
21 Jiang C, Liu B, Chen S, Peng Z, Xie X, Kuang M. Safety margin after radiofrequency ablation of hepatocellular carcinoma: precise assessment with a three-dimensional reconstruction technique using CT imaging. Int J Hyperthermia. 2018;34:1135-1141. [PMID: 29392978 DOI: 10.1080/02656736.2017.1411981] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
22 Numata K, Fukuda H, Morimoto M, Kondo M, Nozaki A, Oshima T, Okada M, Takebayashi S, Maeda S, Tanaka K. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma. Eur J Radiol. 2012;81:2746-2753. [PMID: 22197088 DOI: 10.1016/j.ejrad.2011.11.052] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
23 Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 2013;30:381. [PMID: 23292867 DOI: 10.1007/s12032-012-0381-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
24 Schwartz M, Roayaie S, Uva P. Treatment of HCC in patients awaiting liver transplantation. Am J Transplant. 2007;7:1875-1881. [PMID: 17532747 DOI: 10.1111/j.1600-6143.2007.01863.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
25 Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2006;60:89-98. [DOI: 10.1016/j.critrevonc.2006.06.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 6.9] [Reference Citation Analysis]
26 Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20:10223-10237. [PMID: 25132740 DOI: 10.3748/wjg.v20.i30.10223] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 39] [Article Influence: 7.2] [Reference Citation Analysis]
27 Osaki Y, Nishikawa H. Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res 2015;45:59-74. [PMID: 24965914 DOI: 10.1111/hepr.12378] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 7.4] [Reference Citation Analysis]
28 Shiina S, Tateishi R, Imamura M, Teratani T, Koike Y, Sato S, Obi S, Kanai F, Kato N, Yoshida H. Percutaneous ethanol injection for hepatocellular carcinoma: 20-year outcome and prognostic factors. Liver Int. 2012;32:1434-1442. [PMID: 22712520 DOI: 10.1111/j.1478-3231.2012.02838.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
29 Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastro 2004;7:431-41. [DOI: 10.1007/s11938-004-0002-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
30 de la Serna S, Vilana R, Sánchez-Cabús S, Calatayud D, Ferrer J, Molina V, Fondevila C, Bruix J, Fuster J, García-Valdecasas JC. Results of laparoscopic radiofrequency ablation for HCC. Could the location of the tumour influence a complete response to treatment? A single European centre experience. HPB (Oxford). 2015;17:387-393. [PMID: 25545319 DOI: 10.1111/hpb.12379] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
31 Kokabi N, Xing M, Duszak R Jr, Duszak R Jr, Howard DH, Applegate KE, Camacho JC, Kim HS. Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study. Future Oncol 2016;12:183-98. [PMID: 26690268 DOI: 10.2217/fon.15.242] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
32 Kolokythas O, Gauthier T, Fernandez AT, Xie H, Timm BA, Cuevas C, Dighe MK, Mitsumori LM, Bruce MF, Herzka DA, Goswami GK, Andrews RT, Oas KM, Dubinsky TJ, Warren BH. Ultrasound-Based Elastography: A Novel Approach to Assess Radio Frequency Ablation of Liver Masses Performed With Expandable Ablation Probes: A Feasibility Study. Journal of Ultrasound in Medicine 2008;27:935-46. [DOI: 10.7863/jum.2008.27.6.935] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
33 Amorim J, França M, Perez-girbes A, Torregrosa A, Martí-bonmatí L. Critical review of HCC imaging in the multidisciplinary setting: treatment allocation and evaluation of response. Abdom Radiol 2020;45:3119-28. [DOI: 10.1007/s00261-020-02470-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
34 Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One 2013;8:e80276. [PMID: 24244668 DOI: 10.1371/journal.pone.0080276] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
35 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 113] [Article Influence: 10.7] [Reference Citation Analysis]
36 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 106] [Article Influence: 11.3] [Reference Citation Analysis]
37 Memeo R, de Blasi V, Cherkaoui Z, Dehlawi A, De' Angelis N, Piardi T, Sommacale D, Marescaux J, Mutter D, Pessaux P. New Approaches in Locoregional Therapies for Hepatocellular Carcinoma. J Gastrointest Cancer 2016;47:239-46. [PMID: 27270711 DOI: 10.1007/s12029-016-9840-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
38 Carberry GA, Smolock AR, Cristescu M, Wells SA, Ziemlewicz TJ, Lubner MG, Hinshaw JL, Brace CL, Lee FT. Safety and Efficacy of Percutaneous Microwave Hepatic Ablation Near the Heart. Journal of Vascular and Interventional Radiology 2017;28:490-7. [DOI: 10.1016/j.jvir.2016.12.1216] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
39 Kim SH, Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, Choi D, Lee WJ, Lim HK. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2009;192:1675-1681. [PMID: 19457834 DOI: 10.2214/ajr.08.1262] [Cited by in Crossref: 243] [Cited by in F6Publishing: 83] [Article Influence: 20.3] [Reference Citation Analysis]
40 Vilana R, Bianchi L, Varela M, Nicolau C, Sánchez M, Ayuso C, García M, Sala M, Llovet JM, Bruix J. Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma? Eur Radiol. 2006;16:2454-2462. [PMID: 16710666 DOI: 10.1007/s00330-006-0264-8] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
41 Díaz-Sánchez A, Matilla A, Núñez O, Merino B, Peligros I, Rincón D, Salcedo M, Lo Iacono O, Vega Catalina M, Clemente G, Bañares R. [Influence of treatment of hepatocellular carcinoma before liver transplantation on post transplant tumor recurrence and survival]. Gastroenterol Hepatol 2010;33:155-64. [PMID: 19945770 DOI: 10.1016/j.gastrohep.2009.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
42 Liu Q, Zhao H, Wu S, Zhao X, Zhong Y, Li L, Liu Z. Impact of microbubble-enhanced ultrasound on liver ethanol ablation. Ultrasound Med Biol 2013;39:1039-46. [PMID: 23499347 DOI: 10.1016/j.ultrasmedbio.2013.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
43 Nemes B, Gelley F, Piros L, Zádori G, Görög D, Fehérvári I, Kóbori L, Sárváry E, Nagy P, Kiss A, Doros A. The impact of Milan criteria on liver transplantation for hepatocellular carcinoma: first 15 years' experience of the Hungarian Liver Transplant Program. Transplant Proc 2011;43:1272-4. [PMID: 21620108 DOI: 10.1016/j.transproceed.2011.03.077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
44 Gao TM, Bai DS, Qian JJ, Zhang C, Jin SJ, Jiang GQ. The growth rate of hepatocellular carcinoma is different with different TNM stages at diagnosis. Hepatobiliary Pancreat Dis Int 2021;20:330-6. [PMID: 33637452 DOI: 10.1016/j.hbpd.2021.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Odisio BC, Wallace MJ. Image-guided interventions in oncology. Surg Oncol Clin N Am 2014;23:937-55. [PMID: 25246055 DOI: 10.1016/j.soc.2014.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sherman M. Hepatitis C and Hepatocellular Carcinoma: Grist for the Mill. Gastroenterology 2009;136:39-42. [DOI: 10.1053/j.gastro.2008.11.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
47 Wang T, Lu XJ, Chi JC, Ding M, Zhang Y, Tang XY, Li P, Zhang L, Zhang XY, Zhai B. Microwave ablation of hepatocellular carcinoma as first-line treatment: long term outcomes and prognostic factors in 221 patients. Sci Rep 2016;6:32728. [PMID: 27620527 DOI: 10.1038/srep32728] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
48 Kitisin K, Packiam V, Steel J, Humar A, Gamblin TC, Geller DA, Marsh JW, Tsung A. Presentation and outcomes of hepatocellular carcinoma patients at a western centre. HPB (Oxford) 2011;13:712-22. [PMID: 21929672 DOI: 10.1111/j.1477-2574.2011.00362.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
49 Choi YR, Chung JW, Yu MH, Lee M, Kim JH. Diagnostic accuracy of contrast-enhanced dynamic CT for small hypervascular hepatocellular carcinoma and assessment of dynamic enhancement patterns: Results of two-year follow-up using cone-beam CT hepatic arteriography. PLoS One. 2018;13:e0203940. [PMID: 30231076 DOI: 10.1371/journal.pone.0203940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
50 Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. JHEP Rep 2020;2:100100. [PMID: 32514496 DOI: 10.1016/j.jhepr.2020.100100] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
51 Fu Y, Xi M, Pan Y, Chen J, Wang J, Liu S, Xu L, Zhou Z, Liu M, Chen M, Zhao L, Zhang Y. Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort Study. J Oncol 2020;2020:4835653. [PMID: 32565803 DOI: 10.1155/2020/4835653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Cabibbo G, Genco C, Di Marco V, Barbara M, Enea M, Parisi P, Brancatelli G, Romano P, Craxì A, Cammà C. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation: Predicting survival after TACE for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2011;34:196-204. [DOI: 10.1111/j.1365-2036.2011.04694.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
53 Huo T, Lin H, Hsia C, Wu J, Lee P, Chi C, Lee S. The Model for End-Stage Liver Disease Based Cancer Staging Systems Are Better Prognostic Models for Hepatocellular Carcinoma: A Prospective Sequential Survey. Am J Gastroenterology 2007;102:1920-30. [DOI: 10.1111/j.1572-0241.2007.01370.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]
54 Ayuso C, Rimola J, García-Criado A. Imaging of HCC. Abdom Imaging. 2012;37:215-230. [PMID: 21909721 DOI: 10.1007/s00261-011-9794-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
55 Fahrner R, Dondorf F, Ardelt M, Dittmar Y, Settmacher U, Rauchfuß F. Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol 2015;21:12071-82. [PMID: 26576092 DOI: 10.3748/wjg.v21.i42.12071] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
56 Chen T, Chang T, Huang P, Tsai M, Lin L, Liu C, Ho K, Siauw C, Chao P, Tung J. Management and patient survival in hepatocellular carcinoma: Does the physician's level of experience matter? Journal of Gastroenterology and Hepatology 2008;23:e179-88. [DOI: 10.1111/j.1440-1746.2008.05341.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
57 Kalra N, Kang M, Bhatia A, Duseja AK, Dhiman RK, Arya VK, Rajwanshi A, Chawla YK, Khandelwal N. Role of radiofrequency ablation in unresectable hepatocellular carcinoma: An Indian experience. Indian J Radiol Imaging. 2013;23:139-144. [PMID: 24082478 DOI: 10.4103/0971-3026.116569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
58 Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Glória H, Marinho R, Távora I, Ramalho F. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26:680-687. [PMID: 16842324 DOI: 10.1111/j.1478-3231.2006.001285.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
59 Tinguely P, Frehner L, Lachenmayer A, Banz V, Weber S, Candinas D, Maurer MH. Stereotactic Image-Guided Microwave Ablation for Malignant Liver Tumors-A Multivariable Accuracy and Efficacy Analysis. Front Oncol. 2020;10:842. [PMID: 32587826 DOI: 10.3389/fonc.2020.00842] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
60 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 82] [Article Influence: 21.6] [Reference Citation Analysis]
61 Kim DY, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Kim SU, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma. Aliment Pharmacol Ther. 2012;35:1343-1350. [PMID: 22486716 DOI: 10.1111/j.1365-2036.2012.05089.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 7.0] [Reference Citation Analysis]
62 Sherman M. Diagnosis of small hepatocellular carcinoma. Hepatology 2005;42:14-6. [DOI: 10.1002/hep.20790] [Cited by in Crossref: 76] [Cited by in F6Publishing: 35] [Article Influence: 4.8] [Reference Citation Analysis]
63 Serra C, Cucchetti A, Felicani C, Mosconi C, De Cinque A, Golfieri R, Andreone P, Ercolani G, Maroni L, Ravaioli M, D'Errico A, Pinna AD, Cescon M. Assessment of Radiofrequency Ablation Efficacy for Hepatocellular Carcinoma by Histology and Pretransplant Radiology. Liver Transpl 2019;25:88-97. [PMID: 30415500 DOI: 10.1002/lt.25381] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
64 Guglielmi A, Ruzzenente A, Valdegamberi A, Pachera S, Campagnaro T, D’Onofrio M, Martone E, Nicoli P, Iacono C. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg. 2008;12:192-198. [PMID: 17999123 DOI: 10.1007/s11605-007-0392-8] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 7.9] [Reference Citation Analysis]
65 Olivo M, Valenza F, Buccellato A, Scala L, Virdone R, Sciarrino E, Di Piazza S, Marrone C, Orlando A, Fusco G. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis. 2010;42:515-519. [PMID: 19914153 DOI: 10.1016/j.dld.2009.09.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
66 Sacilotto N, Castillo J, Riffo-Campos ÁL, Flores JM, Hibbitt O, Wade-Martins R, López C, Rodrigo MI, Franco L, López-Rodas G. Growth Arrest Specific 1 (Gas1) Gene Overexpression in Liver Reduces the In Vivo Progression of Murine Hepatocellular Carcinoma and Partially Restores Gene Expression Levels. PLoS One 2015;10:e0132477. [PMID: 26161998 DOI: 10.1371/journal.pone.0132477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
67 Zech CJ, Bartolozzi C, Bioulac-sage P, Chow PK, Forner A, Grazioli L, Huppertz A, Laumonier H, Min Lee J, Murakami T, Ricke J, Sirlin CB. Consensus Report of the Fifth International Forum for Liver MRI. American Journal of Roentgenology 2013;201:97-107. [DOI: 10.2214/ajr.12.9491] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
68 Sherman M. How to improve HCC surveillance outcomes. JHEP Rep 2019;1:460-7. [PMID: 32039398 DOI: 10.1016/j.jhepr.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
69 Obara K, Matsumoto N, Okamoto M, Kobayashi M, Ikeda H, Takahashi H, Katakura Y, Matsunaga K, Ishii T, Okuse C. Insufficient radiofrequency ablation therapy may induce further malignant transformation of hepatocellular carcinoma. Hepatol Int. 2008;2:116-123. [PMID: 19669287 DOI: 10.1007/s12072-007-9040-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
70 Catalano O, Izzo F, Vallone P, Sandomenico F, Albino V, Nunziata A, Fusco R, Petrillo A. Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience. Acta Radiol 2015;56:133-42. [PMID: 24523360 DOI: 10.1177/0284185114521108] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
71 Sulaiman AS, Gani RA, Hasan I, Lesmana CRA, Kurniawan J, Jasirwan COM, Kalista KF, Nababan SHH, Aprilicia G, Lesmana LA. Overall Survival of Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation (RFA) Treatment: a Retrospective Cohort Study from Two Referral Hospitals in Indonesia. J Gastrointest Cancer 2021. [PMID: 34379264 DOI: 10.1007/s12029-021-00676-0] [Reference Citation Analysis]
72 Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, Mizuno T, Yashiro K, Nisimura S, Kunieda E. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:372-379. [PMID: 23927053 DOI: 10.1111/jgh.12350] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 8.3] [Reference Citation Analysis]
73 Salvatore V, Gianstefani A, Negrini G, Allegretti G, Galassi M, Piscaglia F. Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVue®. Liver Cancer 2016;5:55-66. [PMID: 29234627 DOI: 10.1159/000367748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
74 Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, Goto T, Yoshida H, Omata M, Koike K. Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol. 2012;107:569-77; quiz 578. [PMID: 22158026 DOI: 10.1038/ajg.2011.425] [Cited by in Crossref: 406] [Cited by in F6Publishing: 365] [Article Influence: 40.6] [Reference Citation Analysis]
75 Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. Radiofrequency ablation is better than surgical resection in patients with hepatocellular carcinoma within the Milan criteria and preserved liver function: a retrospective study using propensity score analyses. J Clin Gastroenterol. 2015;49:242-249. [PMID: 24714185 DOI: 10.1097/mcg.0000000000000133] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
76 Zhou Y, Yang Y, Zhou B, Wang Z, Zhu R, Chen X, Ouyang J, Li Q, Zhou J. Challenges Facing Percutaneous Ablation in the Treatment of Hepatocellular Carcinoma: Extension of Ablation Criteria. J Hepatocell Carcinoma 2021;8:625-44. [PMID: 34189133 DOI: 10.2147/JHC.S298709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Gu YK, Luo RG, Huang JH, Si Tu QJ, Li XX, Gao F. Transarterial embolization ablation of hepatocellular carcinoma with a lipiodol-ethanol mixture. World J Gastroenterol 2010;16:5766-72. [PMID: 21128329 DOI: 10.3748/wjg.v16.i45.5766] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
78 Ju JX, Zeng QJ, Xu EJ, He XQ, Tan L, Huang QN, Li K, Zheng RQ. Intraprocedural contrast-enhanced ultrasound-CT/MR fusion imaging assessment in HCC thermal ablation to reduce local tumor progression: compared with routine contrast-enhanced ultrasound. Int J Hyperthermia 2019;36:785-93. [PMID: 31431086 DOI: 10.1080/02656736.2019.1640899] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
79 Varela M, Sanchez W, Bruix J, Gores GJ. Hepatocellular carcinoma in the setting of liver transplantation. Liver Transpl. 2006;12:1028-1036. [PMID: 16799950 DOI: 10.1002/lt.20833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
80 Kim G, Shim JH, Kim M, Kim SY, Won HJ, Shin YM, Kim PN, Kim K, Lee S, Lee HC. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. British Journal of Surgery 2016;103:126-35. [DOI: 10.1002/bjs.9960] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 9.3] [Reference Citation Analysis]
81 Zhang F, Wu G, Sun H, Ding J, Xia F, Li X, Ma K, Wang S, Bie P. Radiofrequency ablation of hepatocellular carcinoma in elderly patients fitting the Milan criteria: a single centre with 13 years experience. Int J Hyperthermia 2014;30:471-9. [PMID: 25314335 DOI: 10.3109/02656736.2014.961042] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
82 Lee YB, Lee DH, Cho Y, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim HC, Yi NJ, Lee KW. Comparison of transarterial chemoembolization and hepatic resection for large solitary hepatocellular carcinoma: a propensity score analysis. J Vasc Interv Radiol. 2015;26:651-659. [PMID: 25824316 DOI: 10.1016/j.jvir.2015.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
83 Sato Y, Watanabe H, Sone M, Onaya H, Sakamoto N, Osuga K, Takahashi M, Arai Y. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. Ups J Med Sci. 2013;118:16-22. [PMID: 23167460 DOI: 10.3109/03009734.2012.729104] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
84 Forner A, Reig M, Varela M, Burrel M, Feliu J, Briceño J, Sastre J, Martí-Bonmati L, Llovet JM, Bilbao JI, Sangro B, Pardo F, Ayuso C, Bru C, Tabernero J, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH]. Med Clin (Barc) 2016;146:511.e1-511.e22. [PMID: 26971984 DOI: 10.1016/j.medcli.2016.01.028] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
85 Nicolau C, Bru C. Characterisation of Hepatocellular Carcinoma in Cirrhosis. In: Lencioni R, editor. Enhancing the Role of Ultrasound with Contrast Agents. Milan: Springer-Verlag; 2006. pp. 39-52. [DOI: 10.1007/88-470-0476-4_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
86 Llovet JM, De Baere T, Kulik L, Haber PK, Greten TF, Meyer T, Lencioni R. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:293-313. [PMID: 33510460 DOI: 10.1038/s41575-020-00395-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
87 Hirata K, Nakaura T, Okuaki T, Tsuda N, Taguchi N, Oda S, Utsunomiya D, Yamashita Y. 3D hybrid profile order technique in a single breath-hold 3D T2-weighted fast spin-echo sequence: Usefulness in diagnosis of small liver lesions. European Journal of Radiology 2018;98:113-7. [DOI: 10.1016/j.ejrad.2017.11.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: A meta-analysis. Journal of Hepatology 2010;52:380-8. [DOI: 10.1016/j.jhep.2009.12.004] [Cited by in Crossref: 186] [Cited by in F6Publishing: 163] [Article Influence: 16.9] [Reference Citation Analysis]
89 Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535-1547. [PMID: 16696801 DOI: 10.1111/j.1365-2036.2006.02932.x] [Cited by in Crossref: 250] [Cited by in F6Publishing: 215] [Article Influence: 16.7] [Reference Citation Analysis]
90 Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, Fukuda K, Igura T, Sawai Y, Morimoto O, Hori M, Nagano H, Wakasa K, Hayashi N, Murakami T. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010;20:2405-13. [PMID: 20490505 DOI: 10.1007/s00330-010-1812-9] [Cited by in Crossref: 176] [Cited by in F6Publishing: 153] [Article Influence: 16.0] [Reference Citation Analysis]
91 Francica G, Petrolati A, Di Stasio E, Pacella S, Stasi R, Pacella CM. Influence of ablative margin on local tumor progression and survival in patients with HCC ≤4 cm after laser ablation. Acta Radiol. 2012;53:394-400. [PMID: 22393158 DOI: 10.1258/ar.2012.110471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
92 De Giorgio M, Vezzoli S, Cohen E, Armellini E, Lucà MG, Verga G, Pinelli D, Nani R, Valsecchi MG, Antolini L. Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria. Liver Transpl. 2010;16:503-512. [PMID: 20373461 DOI: 10.1002/lt.22039] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
93 Nakazawa T, Kokubu S, Shibuya A, Ono K, Watanabe M, Hidaka H, Tsuchihashi T, Saigenji K. Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative Margin. American Journal of Roentgenology 2007;188:480-8. [DOI: 10.2214/ajr.05.2079] [Cited by in Crossref: 242] [Cited by in F6Publishing: 88] [Article Influence: 17.3] [Reference Citation Analysis]
94 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
95 Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF, Carrillo-Pérez DL. Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol 2015;7:362-76. [PMID: 25848464 DOI: 10.4254/wjh.v7.i3.362] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
96 Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term Outcomes. Gastroenterology 2010;138:52-64. [DOI: 10.1053/j.gastro.2009.09.006] [Cited by in Crossref: 650] [Cited by in F6Publishing: 535] [Article Influence: 59.1] [Reference Citation Analysis]
97 Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062-1069. [PMID: 20233824 DOI: 10.1001/jama.2010.262] [Cited by in Crossref: 140] [Cited by in F6Publishing: 122] [Article Influence: 12.7] [Reference Citation Analysis]
98 Tremosini S, Reig M, de Lope CR, Forner A, Bruix J. Treatment of early hepatocellular carcinoma: Towards personalized therapy. Dig Liver Dis. 2010;42 Suppl 3:S242-S248. [PMID: 20547310 DOI: 10.1016/s1590-8658(10)60512-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
99 Pacella CM, Francica G, Di Lascio FM, Arienti V, Antico E, Caspani B, Magnolfi F, Megna AS, Pretolani S, Regine R. Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis. J Clin Oncol. 2009;27:2615-2621. [PMID: 19332729 DOI: 10.1200/jco.2008.19.0082] [Cited by in Crossref: 86] [Cited by in F6Publishing: 22] [Article Influence: 7.2] [Reference Citation Analysis]
100 Francica G, Saviano A, De Sio I, De Matthaeis N, Brunello F, Cantamessa A, Giorgio A, Scognamiglio U, Fornari F, Giangregorio F, Piscaglia F, Gualandi S, Caturelli E, Roselli P, Rapaccini GL, Pompili M. Long-term effectiveness of radiofrequency ablation for solitary small hepatocellular carcinoma: a retrospective analysis of 363 patients. Dig Liver Dis. 2013;45:336-341. [PMID: 23245589 DOI: 10.1016/j.dld.2012.10.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
101 Li L, Yeo W. Value of quality of life analysis in liver cancer: A clinician's perspective. World J Hepatol. 2017;9:867-883. [PMID: 28804570 DOI: 10.4254/wjh.v9.i20.867] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
102 Khan AS, Hussain HK, Johnson TD, Weadock WJ, Pelletier SJ, Marrero JA. Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging. 2010;32:360-366. [PMID: 20677263 DOI: 10.1002/jmri.22271] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 7.7] [Reference Citation Analysis]
103 Pompili M, Nicolardi E, Abbate V, Miele L, Riccardi L, Covino M, De Matthaeis N, Grieco A, Landolfi R, Rapaccini GL. Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2011;17:3126-32. [PMID: 21912455 DOI: 10.3748/wjg.v17.i26.3126] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
104 Yaghmai V, Miller FH, Rezai P, Benson AB 3rd, Salem R. Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. AJR Am J Roentgenol 2011;197:18-27. [PMID: 21701006 DOI: 10.2214/AJR.11.6581] [Cited by in Crossref: 42] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
105 Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Ogura T, Hagihara A, Iwasa S. A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolization. Cancer Chemother Pharmacol 2008;61:683-8. [DOI: 10.1007/s00280-007-0523-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
106 Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012;10:354-362. [PMID: 22083023 DOI: 10.1016/j.cgh.2011.11.008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
107 Yu MH, Kim JH, Yoon J, Kim H, Chung JW, Han JK, Choi B. Small (≤1-cm) Hepatocellular Carcinoma: Diagnostic Performance and Imaging Features at Gadoxetic Acid–enhanced MR Imaging. Radiology 2014;271:748-60. [DOI: 10.1148/radiol.14131996] [Cited by in Crossref: 63] [Cited by in F6Publishing: 60] [Article Influence: 9.0] [Reference Citation Analysis]
108 Lencioni R, Crocetti L, Cioni D, Pina CD, Oliveri F, De Simone P, Brunetto M, Filipponi F. Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multipronged injection needle: results of a pilot clinical study. J Vasc Interv Radiol. 2010;21:1533-1538. [PMID: 20817558 DOI: 10.1016/j.jvir.2010.06.019] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
109 Wong SN, Lin CJ, Lin CC, Chen WT, Cua IH, Lin SM. Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations. AJR Am J Roentgenol. 2008;190:W187-W195. [PMID: 18287411 DOI: 10.2214/ajr.07.2537] [Cited by in Crossref: 57] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
110 Nicolini A, Crespi S, Martinetti L. Drug delivery embolization systems: a physician's perspective. Expert Opin Drug Deliv 2011;8:1071-84. [PMID: 21692688 DOI: 10.1517/17425247.2011.590472] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
111 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 24] [Article Influence: 0.6] [Reference Citation Analysis]
112 Koda M, Mandai M, Matono T, Sugihara T, Nagahara T, Ueki M, Ohyama K, Hosho K, Murawaki Y. Assessment of the ablated area after radiofrequency ablation by contrast-enhanced sonography; comparison with virtual sonography with magnetic navigation. Clinical Imaging 2010;34:60-4. [DOI: 10.1016/j.clinimag.2009.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
113 Kang H, Lee HY, Lee KS, Kim JH. Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol 2012;13:371-90. [PMID: 22778559 DOI: 10.3348/kjr.2012.13.4.371] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
114 Xu Y, Shen Q, Wang N, Wu PP, Huang B, Kuang M, Qian GJ. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. Chin J Cancer 2017;36:14. [PMID: 28103953 DOI: 10.1186/s40880-017-0183-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
115 Rimola J, Davenport MS, Liu PS, Brown T, Marrero JA, Mckenna BJ, Hussain HK. Diagnostic accuracy of MRI with extracellular vs. hepatobiliary contrast material for detection of residual hepatocellular carcinoma after locoregional treatment. Abdom Radiol 2019;44:549-58. [DOI: 10.1007/s00261-018-1775-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
116 Forner A, Bruix J. Ablation for hepatocellular carcinoma: Is there need to have a winning technique? J Hepatol. 2010;52:310-312. [PMID: 20133005 DOI: 10.1016/j.jhep.2009.11.024] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
117 Santambrogio R, Barabino M, Bruno S, Costa M, Ceretti AP, Angiolini MR, Zuin M, Meloni F, Opocher E. Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: a single European center experience of 426 patients. Surg Endosc. 2015;Epub ahead of print. [PMID: 26275555 DOI: 10.1007/s00464-015-4468-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
118 Putzer D, Schullian P, Braunwarth E, Fodor M, Primavesi F, Cardini B, Resch T, Oberhuber R, Maglione M, Margreiter C, Schneeberger S, Stättner S, Öfner-Velano D, Jaschke W, Bale RJ. Integrating interventional oncology in the treatment of liver tumors. Eur Surg 2018;50:117-24. [PMID: 29875800 DOI: 10.1007/s10353-018-0521-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
119 Su T, Liao J, Dai Z, Xu L, Chen S, Wang Y, Peng Z, Zhang Q, Peng S, Kuang M. Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation. Oncogene 2018;37:3514-27. [DOI: 10.1038/s41388-018-0169-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
120 Tsai S, Pawlik TM. Outcomes of ablation versus resection for colorectal liver metastases: are we comparing apples with oranges? Ann Surg Oncol 2009;16:2422-8. [PMID: 19554378 DOI: 10.1245/s10434-009-0491-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
121 Kim MN, Kim BK, Han K, Kim SU. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment. Expert Review of Gastroenterology & Hepatology 2014;9:335-48. [DOI: 10.1586/17474124.2015.959929] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
122 Sherman M. Primary Malignant Neoplasms of the Liver. In: Dooley JS, Lok ASF, Burroughs AK, Heathcote EJ, editors. Sherlock's Diseases of the Liver and Biliary System. Oxford: Wiley-Blackwell; 2011. pp. 681-703. [DOI: 10.1002/9781444341294.ch35] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
123 Sherman M. Chronic hepatitis C and screening for hepatocellular carcinoma. Clin Liver Dis. 2006;10:735-752. [PMID: 17164115 DOI: 10.1016/j.cld.2006.08.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
124 Wong SN, Santi GE, Nurjadin H, Aguilar R, Gosalvez-Pe S. Temperature-dependent electrode repositioning for multiple overlapping radiofrequency ablation in ex vivo porcine livers. J Vasc Interv Radiol 2010;21:1733-8. [PMID: 20884231 DOI: 10.1016/j.jvir.2010.07.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Kang SH, Yim HJ, Kim SY, Suh SJ, Hyun JJ, Jung SW, Jung YK, Koo JS, Lee SW. Proton Pump Inhibitor Therapy Is Associated With Reduction of Early Bleeding Risk After Prophylactic Endoscopic Variceal Band Ligation: A Retrospective Cohort Study. Medicine (Baltimore) 2016;95:e2903. [PMID: 26937932 DOI: 10.1097/MD.0000000000002903] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
126 Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. Journal of Hepatology 2019;70:1262-77. [DOI: 10.1016/j.jhep.2019.01.028] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 29.5] [Reference Citation Analysis]
127 Latteri F, Sandonato L, Di Marco V, Parisi P, Cabibbo G, Lombardo G, Galia M, Midiri M, Latteri MA, Craxì A. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig Liver Dis. 2008;40:684-689. [PMID: 18294940 DOI: 10.1016/j.dld.2007.12.021] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
128 Forner A, Ayuso C, Varela M, Rimola J, Hessheimer AJ, de Lope CR, Reig M, Bianchi L, Llovet JM, Bruix J. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616-623. [PMID: 19117042 DOI: 10.1002/cncr.24050] [Cited by in Crossref: 303] [Cited by in F6Publishing: 272] [Article Influence: 25.3] [Reference Citation Analysis]
129 Huo TI, Huang YH, Huang HC, Wu JC, Lee PC, Chang FY, Lee SD. Fever and infectious complications after percutaneous acetic acid injection therapy for hepatocellular carcinoma: incidence and risk factor analysis. J Clin Gastroenterol 2006;40:639-42. [PMID: 16917410 DOI: 10.1097/00004836-200608000-00017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
130 Jeong Y, Jung J, Cho B, Kwak J, Jeong C, Kim JH, Park JH, Kim SY, Shim JH, Kim KM, Lim YS, Lee HC, Yoon SM. Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. BMC Cancer. 2018;18:416. [PMID: 29653562 DOI: 10.1186/s12885-018-4340-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
131 Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol. 2007;25:978-986. [PMID: 17350947 DOI: 10.1200/jco.2006.09.8657] [Cited by in Crossref: 129] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
132 Bhangoo MS, Karnani DR, Hein PN, Giap H, Knowles H, Issa C, Steuterman S, Pockros P, Frenette C. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma. J Gastrointest Oncol 2015;6:469-78. [PMID: 26487939 DOI: 10.3978/j.issn.2078-6891.2015.056] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
133 Rimola J, Forner A, Sapena V, Llarch N, Darnell A, Díaz A, García-criado A, Bianchi L, Vilana R, Díaz-gonzález Á, Ayuso C, Bruix J, Reig M. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma. Eur Radiol 2020;30:186-94. [DOI: 10.1007/s00330-019-06351-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
134 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723-750. [PMID: 29624699 DOI: 10.1002/hep.29913] [Cited by in Crossref: 1126] [Cited by in F6Publishing: 917] [Article Influence: 563.0] [Reference Citation Analysis]
135 Quetglas IM, Moeini A, Pinyol R, Llovet JM. Integration of genomic information in the clinical management of HCC. Best Pract Res Clin Gastroenterol 2014;28:831-42. [PMID: 25260311 DOI: 10.1016/j.bpg.2014.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
136 Yang YP, Qu JH, Chang XJ, Lu YY, Bai WL, Dong Z, Wang H, An LJ, Xu ZX, Wang CP. High intratumoral metastasis-associated in colon cancer-1 expression predicts poor outcomes of cryoablation therapy for advanced hepatocellular carcinoma. J Transl Med. 2013;11:41. [PMID: 23414367 DOI: 10.1186/1479-5876-11-41] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
137 Yoon SM, Lim YS, Park MJ, Kim SY, Cho B, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Lee YS, Park JH, Kim JH. Stereotactic body radiation therapy as an alternative treatment for small hepatocellular carcinoma. PLoS One. 2013;8:e79854. [PMID: 24255719 DOI: 10.1371/journal.pone.0079854] [Cited by in Crossref: 100] [Cited by in F6Publishing: 82] [Article Influence: 12.5] [Reference Citation Analysis]
138 Torzilli G, Del Fabbro D, Palmisano A, Marconi M, Makuuchi M, Montorsi M. Salvage hepatic resection after incomplete interstitial therapy for primary and secondary liver tumours. Br J Surg. 2007;94:208-213. [PMID: 17149716 DOI: 10.1002/bjs.5603] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
139 Gallotti A, D’Onofrio M, Ruzzenente A, Martone E, De Robertis R, Guglielmi A, Pozzi Mucelli R. Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma. Radiol Med. 2009;114:1094-1105. [PMID: 19756947 DOI: 10.1007/s11547-009-0436-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
140 Yang B, Zan RY, Wang SY, Li XL, Wei ML, Guo WH, You X, Li J, Liao ZY. Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. World J Surg Oncol. 2015;13:96. [PMID: 25889181 DOI: 10.1186/s12957-015-0516-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
141 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 62] [Article Influence: 96.0] [Reference Citation Analysis]
142 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 254] [Article Influence: 30.3] [Reference Citation Analysis]
143 Kunishi Y, Numata K, Morimoto M, Okada M, Kaneko T, Maeda S, Tanaka K. Efficacy of fusion imaging combining sonography and hepatobiliary phase MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma. AJR Am J Roentgenol. 2012;198:106-114. [PMID: 22194485 DOI: 10.2214/ajr.10.6039] [Cited by in Crossref: 61] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]
144 Taibbi A, Furlan A, Sandonato L, Bova V, Galia M, Marin D, Cabibbo G, Soresi M, Bartolotta TV, Midiri M. Imaging findings of liver resection using a bipolar radiofrequency electrosurgical device--initial observations. Eur J Radiol. 2012;81:663-670. [PMID: 21306849 DOI: 10.1016/j.ejrad.2011.01.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
145 Li H, Guo Z, Si T, Wang H. EASL and mRECIST responses are independent predictors of survival in hepatocellular carcinoma patients treated with cryoablation. Eur J Gastroenterol Hepatol 2013;25:620-7. [PMID: 23325276 DOI: 10.1097/MEG.0b013e32835ced13] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
146 Haber PK, Maier C, Kästner A, Feldbrügge L, Ortiz Galindo SA, Geisel D, Fehrenbach U, Biebl M, Krenzien F, Benzing C, Schöning W, Pratschke J, Schmelzle M. Predicting the Risk of Postoperative Complications in Patients Undergoing Minimally Invasive Resection of Primary Liver Tumors. J Clin Med 2021;10:685. [PMID: 33578875 DOI: 10.3390/jcm10040685] [Reference Citation Analysis]
147 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
148 Iavarone M, Colombo M. HBV-related HCC, clinical issues and therapy. Dig Liver Dis. 2011;43 Suppl 1:S32-S39. [PMID: 21195370 DOI: 10.1016/S1590-8658(10)60690-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
149 Lin CC, Cheng YT, Chen M WT, Lin SM. The Effectiveness of Multiple Electrode Radiofrequency Ablation in Patients with Hepatocellular Carcinoma with Lesions More than 3 cm in Size and Barcelona Clinic Liver Cancer Stage A to B2. Liver Cancer 2016;5:8-20. [PMID: 26989656 DOI: 10.1159/000367755] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
150 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
151 Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther. 2013;13:469-479. [PMID: 23560841 DOI: 10.1586/era.13.21] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
152 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014;20:5935-50. [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 87] [Article Influence: 13.7] [Reference Citation Analysis]
153 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
154 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2006;22:248-53. [DOI: 10.1097/01.mog.0000218961.86182.8c] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 5.1] [Reference Citation Analysis]
155 Kato K, Abe H, Ika M, Yonezawa T, Sato Y, Hanawa N, Shimizu S, Endo S, Matsuo R, Tsubota A. C-Arm Cone Beam Computed Tomography Guidance for Radiofrequency Ablation in Hepatocellular Carcinoma. Oncology. 2017;92:142-152. [PMID: 28052301 DOI: 10.1159/000453665] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
156 Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ; for the Panel of Experts in HCC-Design Clinical Trials. Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma. JNCI: Journal of the National Cancer Institute 2008;100:698-711. [DOI: 10.1093/jnci/djn134] [Cited by in Crossref: 1166] [Cited by in F6Publishing: 1082] [Article Influence: 89.7] [Reference Citation Analysis]
157 Granito A, Galassi M, Piscaglia F, Romanini L, Lucidi V, Renzulli M, Borghi A, Grazioli L, Golfieri R, Bolondi L. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study. Aliment Pharmacol Ther. 2013;37:355-363. [PMID: 23199022 DOI: 10.1111/apt.12166] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 6.1] [Reference Citation Analysis]
158 Hata M, Tokuuye K, Sugahara S, Tohno E, Nakayama H, Fukumitsu N, Mizumoto M, Abei M, Shoda J, Minami M, Akine Y. Proton Beam Therapy for Aged Patients With Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2007;69:805-12. [DOI: 10.1016/j.ijrobp.2007.04.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
159 Schaible J, Lürken L, Wiggermann P, Verloh N, Einspieler I, Zeman F, Schreyer AG, Bale R, Stroszczynski C, Beyer L. Primary efficacy of percutaneous microwave ablation of malignant liver tumors: comparison of stereotactic and conventional manual guidance. Sci Rep 2020;10:18835. [PMID: 33139835 DOI: 10.1038/s41598-020-75925-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
160 Eisenbrey JR, Gabriel H, Savsani E, Lyshchik A. Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies.Abdom Radiol (NY). 2021;46:3579-3595. [PMID: 33825927 DOI: 10.1007/s00261-021-03059-y] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. World J Gastroenterol. 2013;19:1193-1199. [PMID: 23482437 DOI: 10.3748/wjg.v19.i8.1193] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
162 Pierie JEN, Muzikansky A, Tanabe KK, Ott MJ. The Outcome of Surgical Resection Versus Assignment to the Liver Transplant Waiting List for Hepatocellular Carcinoma. Ann Surg Oncol 2005;12:552-60. [DOI: 10.1245/aso.2004.03.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
163 Korean Liver Cancer Study Group and National Cancer Center, Korea. [Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol. 2009;15:391-423. [PMID: 19783891 DOI: 10.3350/kjhep.2009.15.3.391] [Cited by in Crossref: 182] [Cited by in F6Publishing: 177] [Article Influence: 16.5] [Reference Citation Analysis]
164 Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, Iaccarino G, Benassi M, Ettorre GM, Maini CL. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010;51:1377-1385. [PMID: 20720056 DOI: 10.2967/jnumed.110.075861] [Cited by in Crossref: 137] [Cited by in F6Publishing: 116] [Article Influence: 12.5] [Reference Citation Analysis]
165 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1702] [Article Influence: 707.3] [Reference Citation Analysis]
166 Kim YI, Chung JW. Selective or targeted gene/drug delivery for liver tumors: advantages and current status of local delivery. Expert Rev Gastroenterol Hepatol 2008;2:791-802. [PMID: 19090739 DOI: 10.1586/17474124.2.6.791] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
167 Santambrogio R, Opocher E, Costa M, Barabino M, Zuin M, Bertolini E, De Filippi F, Bruno S. Hepatic resection for “BCLC stage A” hepatocellular carcinoma. The prognostic role of alpha-fetoprotein. Ann Surg Oncol. 2012;19:426-434. [PMID: 21732145 DOI: 10.1245/s10434-011-1845-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
168 Benson AB, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw. 2009;7:350-391. [PMID: 19406039 DOI: 10.6004/jnccn.2009.0027] [Cited by in Crossref: 299] [Cited by in F6Publishing: 308] [Article Influence: 24.9] [Reference Citation Analysis]
169 Yin X, Lu M. Percutaneous ablation for small hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;3:121-30. [DOI: 10.1586/egh.09.7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
170 Memon K, Kulik L, Lewandowski RJ, Wang E, Riaz A, Ryu RK, Sato KT, Marshall K, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Senthilnathan S, Baker T, Gates VL, Abecassis M, Benson AB 3rd, Mulcahy MF, Omary RA, Salem R. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011;141:526-35, 535.e1-2. [PMID: 21664356 DOI: 10.1053/j.gastro.2011.04.054] [Cited by in Crossref: 117] [Cited by in F6Publishing: 103] [Article Influence: 11.7] [Reference Citation Analysis]
171 Sherman M. The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol. 2010;105:610-612. [PMID: 20203642 DOI: 10.1038/ajg.2009.663] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
172 Lee SW, Lee HL, Han NI, Jang JW, Bae SH, Choi JY, Yoon SK. Early treatment response to transcatheter arterial chemoembolization is associated with time to the development of extrahepatic metastasis and overall survival in intermediate-stage hepatocellular carcinoma. Cancer Chemother Pharmacol 2017;79:81-8. [PMID: 27913882 DOI: 10.1007/s00280-016-3202-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
173 Al-Rawashdeh FY, Scriven P, Cameron IC, Vergani PV, Wyld L. Unfolded protein response activation contributes to chemoresistance in hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22:1099-1105. [PMID: 20177386 DOI: 10.1097/MEG.0b013e3283378405] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
174 Arienti V, Pretolani S, Pacella CM, Magnolfi F, Caspani B, Francica G, Megna AS, Regine R, Sponza M, Antico E, Di Lascio FML. Complications of Laser Ablation for Hepatocellular Carcinoma: A Multicenter Study. Radiology 2008;246:947-55. [DOI: 10.1148/radiol.2463070390] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
175 Wang T, Zhang XY, Lu X, Zhai B. Laparoscopic Microwave Ablation of Hepatocellular Carcinoma at Liver Surface: Technique Effectiveness and Long-Term Outcomes. Technol Cancer Res Treat 2019;18:1533033818824338. [PMID: 30803390 DOI: 10.1177/1533033818824338] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
176 Wang Y, Zhang L, Li Y, Wang W. Computed tomography-guided percutaneous microwave ablation with artificial ascites for problematic hepatocellular tumors. Int J Hyperthermia 2020;37:256-62. [PMID: 32157926 DOI: 10.1080/02656736.2020.1736649] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
177 Kornberg A. Liver transplantation for hepatocellular carcinoma beyond Milan criteria: multidisciplinary approach to improve outcome. ISRN Hepatol. 2014;25:154-159. [PMID: 27335840 DOI: 10.1155/2014/706945] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
178 Wang Q, Xia D, Bai W, Wang E, Sun J, Huang M, Mu W, Yin G, Li H, Zhao H, Li J, Zhang C, Zhu X, Wu J, Gong W, Li Z, Lin Z, Pan X, Shi H, Shao G, Liu J, Yang S, Zheng Y, Xu J, Song J, Wang W, Wang Z, Zhang Y, Ding R, Zhang H, Yu H, Zheng L, Gu W, You N, Wang G, Zhang S, Feng L, Liu L, Zhang P, Li X, Chen J, Xu T, Zhou W, Zeng H, Huang W, Jiang W, Zhang W, Shao W, Li L, Niu J, Yuan J, Lv Y, Li K, Yin Z, Xia J, Fan D, Han G;  China HCC-TACE Study Group. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. J Hepatol. 2019;70:893-903. [PMID: 30660709 DOI: 10.1016/j.jhep.2019.01.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 25.0] [Reference Citation Analysis]
179 Mlynarsky L, Menachem Y, Shibolet O. Treatment of hepatocellular carcinoma: Steps forward but still a long way to go. World J Hepatol 2015;7:566-74. [PMID: 25848480 DOI: 10.4254/wjh.v7.i3.566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
180 Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK; Interventional Oncology Task Force and Standards Division, Society of Interventional Radiology. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol 2009;20:3-8. [PMID: 18948025 DOI: 10.1016/j.jvir.2008.09.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
181 Isik B, Gonultas F, Sahin T, Yilmaz S. Microvascular Venous Invasion in Hepatocellular Carcinoma: Why Do Recurrences Occur? J Gastrointest Cancer 2020;51:1133-6. [PMID: 32839943 DOI: 10.1007/s12029-020-00487-9] [Reference Citation Analysis]
182 Ishikawa T. Radiofrequency ablation is justified for elderly patients with hepatocellular carcinoma: Editorial. Hepatology Research 2010;40:954-5. [DOI: 10.1111/j.1872-034x.2010.00725.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
183 Kagawa T, Koizumi J, Kojima S, Nagata N, Numata M, Watanabe N, Watanabe T, Mine T. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010;116:3638-3644. [PMID: 20564097 DOI: 10.1002/cncr.25142] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 7.4] [Reference Citation Analysis]
184 Pacella CM, Bizzarri G, Francica G, Forlini G, Petrolati A, Valle D, Anelli V, Bianchini A, Nuntis SD, Pacella S, Rossi Z, Osborn J, Stasi R. Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. Journal of Hepatology 2006;44:902-9. [DOI: 10.1016/j.jhep.2006.01.031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
185 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3770] [Article Influence: 256.5] [Reference Citation Analysis]
186 DuBay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, Ghanekar A, Guba M, Cattral MS, McGilvray ID. Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. HPB (Oxford). 2011;13:24-32. [PMID: 21159100 DOI: 10.1111/j.1477-2574.2010.00228.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
187 Volk ML, Marrero JA. Early detection of liver cancer: diagnosis and management. Curr Gastroenterol Rep. 2008;10:60-66. [PMID: 18417044 DOI: 10.1007/s11894-008-0010-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
188 Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R, Mine N, Kondo Y, Kawabe T, Omata M. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43:1101-1108. [PMID: 16628706 DOI: 10.1002/hep.21164] [Cited by in Crossref: 217] [Cited by in F6Publishing: 188] [Article Influence: 14.5] [Reference Citation Analysis]
189 Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of Hepatocellular Cancer After Resection: Patterns, Treatments, and Prognosis. Annals of Surgery 2015;261:947-55. [DOI: 10.1097/sla.0000000000000710] [Cited by in Crossref: 221] [Cited by in F6Publishing: 124] [Article Influence: 36.8] [Reference Citation Analysis]
190 Mazzaferro V. Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach. Hepatology. 2016;63:1707-1717. [PMID: 26703761 DOI: 10.1002/hep.28420] [Cited by in Crossref: 66] [Cited by in F6Publishing: 58] [Article Influence: 13.2] [Reference Citation Analysis]
191 Cabibbo G, Maida M, Genco C, Alessi N, Peralta M, Butera G, Galia M, Brancatelli G, Genova C, Raineri M, Orlando E, Attardo S, Giarratano A, Midiri M, Di Marco V, Craxì A, Cammà C. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One 2013;8:e70016. [PMID: 23922893 DOI: 10.1371/journal.pone.0070016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
192 Cabibbo G, Craxì A. Needle track seeding following percutaneous procedures for hepatocellular carcinoma. World J Hepatol 2009;1:62-6. [PMID: 21160966 DOI: 10.4254/wjh.v1.i1.62] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
193 Sherman M. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis. 2007;11:817-837, viii. [PMID: 17981230 DOI: 10.1016/j.cld.2007.08.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
194 Yin X, Xie X, Lu M, Xu H, Xu Z, Kuang M, Liu G, Liang J, Lau WY. Percutaneous thermal ablation of medium and large hepatocellular carcinoma: Long-term outcome and prognostic factors. Cancer 2009;115:1914-23. [DOI: 10.1002/cncr.24196] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 8.3] [Reference Citation Analysis]
195 Kuang M, Lu MD, Xie XY, Xu HX, Xu ZF, Liu GJ, Yin XY, Huang JF, Lencioni R. Ethanol ablation of hepatocellular carcinoma Up to 5.0 cm by using a multipronged injection needle with high-dose strategy. Radiology. 2009;253:552-561. [PMID: 19709992 DOI: 10.1148/radiol.2532082021] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
196 Kuang M, Xie XY, Huang C, Wang Y, Lin MX, Xu ZF, Liu GJ, Lu MD. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. J Gastrointest Surg. 2011;15:2165-2171. [PMID: 21972056 DOI: 10.1007/s11605-011-1716-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.0] [Reference Citation Analysis]
197 Real M, Bianchi L, Vilana R, Burrel M, Rimola J. Tratamiento percutáneo e intraarterial del carcinoma hepatocelular. Radiología 2010;52:399-413. [DOI: 10.1016/j.rx.2010.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
198 Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 2009;249:20-25. [PMID: 19106671 DOI: 10.1097/sla.0b013e31818eec29] [Cited by in Crossref: 216] [Cited by in F6Publishing: 78] [Article Influence: 18.0] [Reference Citation Analysis]
199 Kim TH, Park JW, Kim BH, Kim DY, Moon SH, Kim SS, Lee JH, Woo SM, Koh YH, Lee WJ, Kim CM. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017;9:4034-4043. [PMID: 29423102 DOI: 10.18632/oncotarget.23428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
200 Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis. 2011;15:323-324, vii-x. [PMID: 21689616 DOI: 10.1016/j.cld.2011.03.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
201 Berry K, Ioannou GN. Are Patients with Child's A Cirrhosis and Hepatocellular Carcinoma Appropriate Candidates for Liver Transplantation?: Liver Transplantation for Hepatocellular Carcinoma. American Journal of Transplantation 2012;12:706-17. [DOI: 10.1111/j.1600-6143.2011.03853.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
202 Mirdad RS, Madison Hyer J, Diaz A, Tsilimigras DI, Azap RA, Paro A, Pawlik TM. Postoperative imaging surveillance for hepatocellular carcinoma: How much is enough? J Surg Oncol 2021;123:1568-77. [PMID: 33596330 DOI: 10.1002/jso.26433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Nishikawa H, Osaki Y, Iguchi E, Takeda H, Matsuda F, Nakajima J, Sakamoto A, Hatamaru K, Saito S, Nasu A, Kita R, Kimura T. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol 2013;48:951-65. [PMID: 23065022 DOI: 10.1007/s00535-012-0690-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
204 Roayaie S, Bassi D, Tarchi P, Labow D, Schwartz M. Second hepatic resection for recurrent hepatocellular cancer: a Western experience. J Hepatol 2011;55:346-50. [PMID: 21147184 DOI: 10.1016/j.jhep.2010.11.026] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
205 Stevens CL, Awad A, Abbas SM, Watters DAK. Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma. HPB (Oxford) 2017;19:653-8. [PMID: 28427829 DOI: 10.1016/j.hpb.2017.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
206 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3323] [Article Influence: 404.7] [Reference Citation Analysis]
207 Cheung TT, Ma KW, She WH. A review on radiofrequency, microwave and high-intensity focused ultrasound ablations for hepatocellular carcinoma with cirrhosis. Hepatobiliary Surg Nutr 2021;10:193-209. [PMID: 33898560 DOI: 10.21037/hbsn.2020.03.11] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Morimoto M, Numata K, Sugimori K, Shirato K, Kokawa A, Oka H, Hirasawa K, Koh R, Nihommatsu H, Tanaka K. Successful initial ablation therapy contributes to survival in patients with hepatocellular carcinoma. World J Gastroenterol 2007;13:1003-9. [PMID: 17373733 DOI: 10.3748/wjg.v13.i7.1003] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
209 Cao J, Dong Y, Mao F, Wang W. Dynamic Three-Dimensional Contrast-Enhanced Ultrasound to Predict Therapeutic Response of Radiofrequency Ablation in Hepatocellular Carcinoma: Preliminary Findings. Biomed Res Int 2018;2018:6469703. [PMID: 30225261 DOI: 10.1155/2018/6469703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
210 Wu D, Tan M, Zhou M, Sun H, Ji Y, Chen L, Chen G, Zeng M. Liver Computed Tomographic Perfusion in the Assessment of Microvascular Invasion in Patients With Small Hepatocellular Carcinoma: . Investigative Radiology 2015;50:188-94. [DOI: 10.1097/rli.0000000000000098] [Cited by in Crossref: 27] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
211 Lin SM. Local ablation for hepatocellular carcinoma in taiwan. Liver Cancer 2013;2:73-83. [PMID: 24159599 DOI: 10.1159/000343843] [Cited by in Crossref: 26] [Cited by in F6Publishing: 37] [Article Influence: 3.7] [Reference Citation Analysis]
212 Granito A, Bolondi L. Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis. The Lancet Oncology 2017;18:e101-12. [DOI: 10.1016/s1470-2045(16)30569-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 32] [Article Influence: 15.5] [Reference Citation Analysis]
213 Mahnken AH, Bruners P, Günther RW. Techniques of interventional tumor therapy. Dtsch Arztebl Int 2008;105:646-53. [PMID: 19471636 DOI: 10.3238/arztebl.2008.0646] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
214 Takahashi S, Kudo M, Chung H, Inoue T, Ishikawa E, Kitai S, Tatsumi C, Ueda T, Minami Y, Ueshima K, Haji S. Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy. Oncology 2007;72 Suppl 1:98-103. [PMID: 18087189 DOI: 10.1159/000111714] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
215 Kanwal F, Befeler A, Chari RS, Marrero J, Kahn J, Afdhal N, Morgan T, Roberts L, Mohanty SR, Schwartz J. Potentially curative treatment in patients with hepatocellular cancer--results from the liver cancer research network. Aliment Pharmacol Ther. 2012;36:257-265. [PMID: 22670798 DOI: 10.1111/j.1365-2036.2012.05174.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
216 Nishikawa H, Kimura T, Kita R, Osaki Y. Radiofrequency ablation for hepatocellular carcinoma. Int J Hyperthermia. 2013;29:558-568. [PMID: 23937321 DOI: 10.3109/02656736.2013.821528] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
217 Nicolau C, Ripollés T. Contrast-enhanced ultrasound in abdominal imaging. Abdom Imaging 2012;37:1-19. [PMID: 21879317 DOI: 10.1007/s00261-011-9796-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
218 Nault J, Sutter O, Nahon P, Ganne-carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. Journal of Hepatology 2018;68:783-97. [DOI: 10.1016/j.jhep.2017.10.004] [Cited by in Crossref: 99] [Cited by in F6Publishing: 90] [Article Influence: 33.0] [Reference Citation Analysis]
219 Baek CK, Choi JY, Kim KA, Park MS, Lim JS, Chung YE, Kim MJ, Kim KW. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol. 2012;67:148-156. [PMID: 21920517 DOI: 10.1016/j.crad.2011.08.011] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
220 Kuo MJ, Mo LR, Chen CL. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods. BMC Cancer 2021;21:250. [PMID: 33685409 DOI: 10.1186/s12885-021-07948-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Sala M, Varela M, Forner A, Bruix J. [Early diagnosis of liver cancer]. Gastroenterol Hepatol 2005;28:292-7. [PMID: 15871814 DOI: 10.1157/13074066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
222 Schullian P, Johnston EW, Putzer D, Eberle G, Laimer G, Bale R. Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors.Sci Rep. 2020;10:1618. [PMID: 32005871 DOI: 10.1038/s41598-020-58383-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
223 Gish RG. Hepatocellular carcinoma: overcoming challenges in disease management. Clin Gastroenterol Hepatol. 2006;4:252-261. [PMID: 16527686 DOI: 10.1016/j.cgh.2006.01.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 2.7] [Reference Citation Analysis]
224 Schumacher G, Gebauer B. Transarterial chemoembolization for hepatocellular carcinoma with portal vein invasion: a helpful palliative approach. J Gastroenterol Hepatol 2009;24:1317-9. [PMID: 19702898 DOI: 10.1111/j.1440-1746.2009.05976.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
225 Bremner KE, Bayoumi AM, Sherman M, Krahn MD. Management of solitary 1 cm to 2 cm liver nodules in patients with compensated cirrhosis: a decision analysis. Can J Gastroenterol 2007;21:491-500. [PMID: 17703248 DOI: 10.1155/2007/182383] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
226 Cross TJ, Joseph M, Fernando RA, Farrell C, Mitchell JD. The liver to abdominal area ratio (LAAR): a novel imaging score for prognostication in cirrhosis. Aliment Pharmacol Ther 2013;38:1385-94. [PMID: 24138313 DOI: 10.1111/apt.12529] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
227 Pleguezuelo M, Germani G, Marelli L, Xiruochakis E, Misseri M, Manousou P, Arvaniti V, Burroughs AK. Evidence-based diagnosis and locoregional therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2014;2:761-84. [DOI: 10.1586/17474124.2.6.761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
228 Choi SI, Yu A, Kim BH, Ko EJ, Park SS, Nam BH, Park JW. A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score. J Gastroenterol Hepatol 2017;32:651-8. [PMID: 27519171 DOI: 10.1111/jgh.13532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
229 Fuhrmann I, Probst U, Wiggermann P, Beyer L. Navigation Systems for Treatment Planning and Execution of Percutaneous Irreversible Electroporation. Technol Cancer Res Treat 2018;17:1533033818791792. [PMID: 30071779 DOI: 10.1177/1533033818791792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
230 Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 2010;61:317-28. [PMID: 20059340 DOI: 10.1146/annurev.med.080608.100623] [Cited by in Crossref: 160] [Cited by in F6Publishing: 145] [Article Influence: 14.5] [Reference Citation Analysis]
231 Yao FY. Conundrum of treatment for early-stage hepatocellular carcinoma: radiofrequency ablation instead of liver transplantation as the first-line treatment? Liver Transpl. 2014;20:257-260. [PMID: 24493329 DOI: 10.1002/lt.23848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
232 Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017;66:1166-72. [PMID: 28131794 DOI: 10.1016/j.jhep.2017.01.012] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 23.5] [Reference Citation Analysis]
233 Künzli BM, Abitabile P, Maurer CA. Radiofrequency ablation of liver tumors: Actual limitations and potential solutions in the future. World J Hepatol. 2011;3:8-14. [PMID: 21307982 DOI: 10.4254/wjh.v3.i1.8] [Cited by in Crossref: 59] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
234 Lee MW, Kim YJ, Park SW, Hwang JH, Jung SI, Jeon HJ, Kwon WK. Percutaneous radiofrequency ablation of small hepatocellular carcinoma invisible on both ultrasonography and unenhanced CT: a preliminary study of combined treatment with transarterial chemoembolisation. Br J Radiol. 2009;82:908-915. [PMID: 19433482 DOI: 10.1259/bjr/55877882] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
235 Morimoto M, Numata K, Nozawa A, Kondo M, Nozaki A, Nakano M, Tanaka K. Radiofrequency ablation of the liver: extended effect of transcatheter arterial embolization with iodized oil and gelatin sponge on histopathologic changes during follow-up in a pig model. J Vasc Interv Radiol 2010;21:1716-24. [PMID: 20884228 DOI: 10.1016/j.jvir.2010.06.020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
236 Bartolotta TV, Taibbi A, Matranga D, Midiri M, Lagalla R. 3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: preliminary findings. Radiol Med. 2015;Epub ahead of print. [PMID: 25698299 DOI: 10.1007/s11547-015-0514-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
237 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 551] [Article Influence: 44.3] [Reference Citation Analysis]
238 Abdelsalam ME, Murthy R, Avritscher R, Mahvash A, Wallace MJ, Kaseb AO, Odisio BC. Minimally invasive image-guided therapies for hepatocellular carcinoma. J Hepatocell Carcinoma 2016;3:55-61. [PMID: 27785450 DOI: 10.2147/JHC.S92732] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
239 Xia F, Lai EC, Lau WY, Ma K, Li X, Bie P, Qian C. High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma. Ann Surg Oncol 2012;19:1284-91. [PMID: 21913016 DOI: 10.1245/s10434-011-2042-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
240 Sakata J, Shirai Y, Wakai T, Kaneko K, Hatakeyama K. Long-term outcomes after hepatectomy for recurrences after prior local ablation for hepatocellular carcinoma. European Journal of Surgical Oncology (EJSO) 2008;34:433-8. [DOI: 10.1016/j.ejso.2007.03.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
241 Pacella CM, Bizzarri G, Francica G, Bianchini A, De Nuntis S, Pacella S, Crescenzi A, Taccogna S, Forlini G, Rossi Z. Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis. J Vasc Interv Radiol. 2005;16:1447-1457. [PMID: 16319150 DOI: 10.1097/01.rvi.90000172121.82299.38] [Cited by in Crossref: 58] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
242 Kim CJ, Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim M. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int 2014;34:305-12. [DOI: 10.1111/liv.12270] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
243 Kokabi N, Duszak R, Xing M, Howard DH, Applegate KE, Camacho JC, Kim HS. Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study. Future Oncology 2017;13:2021-33. [DOI: 10.2217/fon-2017-0116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
244 Sherman M. Surveillance of Hepatocellular Carcinoma: We Must Do Better. The American Journal of Medicine 2008;121:89-90. [DOI: 10.1016/j.amjmed.2007.11.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
245 Marrero JA, Singal AG. Direct-acting antivirals and recurrence of hepatocellular carcinoma: Marrero and Singal. Liver Transpl 2017;23:1099-100. [DOI: 10.1002/lt.24822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
246 Fujimori M, Takaki H, Nakatsuka A, Uraki J, Yamanaka T, Hasegawa T, Shiraki K, Takei Y, Sakuma H, Yamakado K. Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience. J Vasc Interv Radiol 2013;24:655-66. [PMID: 23428356 DOI: 10.1016/j.jvir.2012.12.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
247 El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, McGlynn KA. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158-166. [PMID: 16290309 DOI: 10.1016/j.jhep.2005.10.002] [Cited by in Crossref: 168] [Cited by in F6Publishing: 147] [Article Influence: 10.5] [Reference Citation Analysis]
248 Kikuchi LO, Paranaguá-vezozzo DC, Chagas AL, Mello ES, Alves VA, Farias AQ, Pietrobon R, Carrilho FJ. Nodules Less Than 20 mm and Vascular Invasion are Predictors of Survival in Small Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2009;43:191-5. [DOI: 10.1097/mcg.0b013e31817ff199] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
249 Tsai W, Cheng J, Lai K, Lin C, Lo G, Hsu P, Yu H, Lin C, Chan H, Chen W, Chen T, Li W, Liang H. Clinical trial: percutaneous acetic acid injection vs. percutaneous ethanol injection for small hepatocellular carcinoma - a long-term follow-up study. Alimentary Pharmacology & Therapeutics 2008;28:304-11. [DOI: 10.1111/j.1365-2036.2008.03702.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
250 Kanda M, Tateishi R, Yoshida H, Sato T, Masuzaki R, Ohki T, Imamura J, Goto T, Hamamura K, Obi S, Kanai F, Shiina S, Omata M. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors. Liver Int. 2008;28:1256-1263. [PMID: 18710423 DOI: 10.1111/j.1478-3231.2008.01864.x] [Cited by in Crossref: 75] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
251 Minami Y, Nishida N, Kudo M. Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI. World J Gastroenterol. 2014;20:4160-4166. [PMID: 24764654 DOI: 10.3748/wjg.v20.i15.4160] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 33] [Article Influence: 7.0] [Reference Citation Analysis]
252 Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henmi S, Hatamaru K, Ishikawa T, Saito S, Nasu A, Kita R, Kimura T, Arimoto A, Osaki Y. Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma. BMC Gastroenterol 2011;11:143. [PMID: 22204311 DOI: 10.1186/1471-230X-11-143] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
253 Chen W, Fernandes ML, Lin C, Lin S. Delay in treatment of early-stage hepatocellular carcinoma using radiofrequency ablation may impact survival of cirrhotic patients in a surveillance program: Delay in RFA for HCC Impacts Survival. J Surg Oncol 2011;103:133-9. [DOI: 10.1002/jso.21797] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
254 Branco F, Brú C, Vilana R, Bianchi L, Alves de Mattos A. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Annals of Hepatology 2009;8:220-7. [DOI: 10.1016/s1665-2681(19)31769-7] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
255 Pacella CM, Francica G, Di Costanzo GG. Laser ablation for small hepatocellular carcinoma. Radiol Res Pract. 2011;2011:595627. [PMID: 22191028 DOI: 10.1155/2011/595627] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
256 Nishigori S, Numata K, Irie K, Fukuda H, Chuma M, Maeda S. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography. J Med Ultrason (2001) 2018;45:405-15. [PMID: 29362966 DOI: 10.1007/s10396-018-0861-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
257 Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl 2016;22:178-87. [PMID: 26479422 DOI: 10.1002/lt.24360] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
258 Lencioni R, Llovet JM. Percutaneous ethanol injection for hepatocellular carcinoma: alive or dead? J Hepatol. 2005;43:377-380. [PMID: 16005537 DOI: 10.1016/j.jhep.2005.06.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
259 Pillai AA, Ramanathan M, Kulik L. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis 2020;24:681-700. [PMID: 33012453 DOI: 10.1016/j.cld.2020.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
260 Gao W, Qiao L, Gao Y, Zhang L, Zhang D, Tu J, Liu Z, Xie F. Effect of microbubble-enhanced ultrasound on percutaneous ethanol ablation of rat walker-256 tumour. Eur Radiol 2016;26:3017-25. [PMID: 26676561 DOI: 10.1007/s00330-015-4153-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
261 Cabibbo G, Latteri F, Antonucci M, Craxì A. Multimodal approaches to the treatment of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009;6:159-69. [DOI: 10.1038/ncpgasthep1357] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.0] [Reference Citation Analysis]
262 Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010;252:903-912. [PMID: 21107100 DOI: 10.1097/sla.0b013e3181efc656] [Cited by in Crossref: 469] [Cited by in F6Publishing: 199] [Article Influence: 42.6] [Reference Citation Analysis]
263 Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol. 2009;20:S342-S347. [PMID: 19560023 DOI: 10.1016/j.jvir.2009.04.029] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
264 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 10.5] [Reference Citation Analysis]
265 Lee YK, Hur W, Lee SW, Hong SW, Kim SW, Choi JE, Yoon SK. Knockdown of 14-3-3ζ enhances radiosensitivity and radio-induced apoptosis in CD133(+) liver cancer stem cells. Exp Mol Med 2014;46:e77. [PMID: 24556826 DOI: 10.1038/emm.2013.151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
266 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
267 Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008;47:82-89. [PMID: 18008357 DOI: 10.1002/hep.21933] [Cited by in Crossref: 705] [Cited by in F6Publishing: 619] [Article Influence: 54.2] [Reference Citation Analysis]
268 Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver Ablation: Best Practice. Radiol Clin North Am 2015;53:933-71. [PMID: 26321447 DOI: 10.1016/j.rcl.2015.05.012] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 7.2] [Reference Citation Analysis]
269 Kikuchi L, Menezes M, Chagas AL, Tani CM, Alencar RS, Diniz MA, Alves VA, D'Albuquerque LA, Carrilho FJ. Percutaneous radiofrequency ablation for early hepatocellular carcinoma: risk factors for survival. World J Gastroenterol 2014;20:1585-93. [PMID: 24587635 DOI: 10.3748/wjg.v20.i6.1585] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
270 Bartolotta TV, Taibbi A, Midiri M, Lagalla R. Contrast-enhanced ultrasound of hepatocellular carcinoma: where do we stand? Ultrasonography 2019;38:200-14. [PMID: 31006227 DOI: 10.14366/usg.18060] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
271 Wu LM, Xu JR, Gu HY, Hua J, Chen J, Zhu J, Zhang W, Hu J. Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease? Dig Dis Sci. 2013;58:3313-3325. [PMID: 23884757 DOI: 10.1007/s10620-013-2790-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
272 Beyer LP, Lürken L, Verloh N, Haimerl M, Michalik K, Schaible J, Stroszczynski C, Wiggermann P. Stereotactically navigated percutaneous microwave ablation (MWA) compared to conventional MWA: a matched pair analysis. Int J Comput Assist Radiol Surg 2018;13:1991-7. [PMID: 29728899 DOI: 10.1007/s11548-018-1778-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
273 Santambrogio R, Bruno S, Kluger MD, Costa M, Salceda J, Belli A, Laurent A, Barabino M, Opocher E, Azoulay D, Cherqui D. Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma. Digestive and Liver Disease 2016;48:189-96. [DOI: 10.1016/j.dld.2015.11.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
274 Kim YS, Lim HK, Rhim H, Lee MW, Choi D, Lee WJ, Paik SW, Koh KC, Lee JH, Choi MS, Gwak GY, Yoo BC. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol. 2013;58:89-97. [PMID: 23023009 DOI: 10.1016/j.jhep.2012.09.020] [Cited by in Crossref: 209] [Cited by in F6Publishing: 177] [Article Influence: 23.2] [Reference Citation Analysis]
275 Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005;11:1505-14. [PMID: 16315294 DOI: 10.1002/lt.20526] [Cited by in Crossref: 209] [Cited by in F6Publishing: 177] [Article Influence: 13.9] [Reference Citation Analysis]
276 Schullian P, Putzer D, Silva MA, Laimer G, Kolbitsch C, Bale R. Stereotactic Radiofrequency Ablation of Liver Tumors in Octogenarians. Front Oncol 2019;9:929. [PMID: 31608232 DOI: 10.3389/fonc.2019.00929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
277 Amini A, Gamblin TC. Palliation: treating patients with inoperable biliary tract and primary liver tumors. Surg Oncol Clin N Am. 2014;23:383-397. [PMID: 24560116 DOI: 10.1016/j.soc.2013.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
278 Le Moigne F, Boussel L, Haquin A, Bancel B, Ducerf C, Berthezène Y, Rode A. Grading of small hepatocellular carcinomas (≤2 cm): correlation between histology, T2 and diffusion-weighted imaging. Br J Radiol 2014;87:20130763. [PMID: 25007142 DOI: 10.1259/bjr.20130763] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
279 Bedossa P, Paradis V. Hepatocellular Carcinoma. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 489-501. [DOI: 10.1016/b978-0-443-06803-4.00035-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]